Seminars in surgical oncology on thyroid cancer

Journal of Surgical Oncology

Volumn 94, Issue 8, 2006, Pages 646-648

  Cady, Blake ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b APC 435 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURGERY; EDITORIAL; HUMAN; MEDICAL EDUCATION; ONCOLOGY; PRIORITY JOURNAL; SURGICAL TRAINING; THYROID CANCER;

AGED; DISEASE MANAGEMENT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 33845441666     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20702     Document Type: Editorial

References (27)

1. Kebebew E, Greenspan FS, Clark OH, et al.: Anaplastic thyroid carcinoma. Cancer 2005;103:1330-1335.
2. Cady B: Presidential address: Beyond risk groups - A new look at differentiated thyroid cancer. Surgery 1998;124:947-957.
3. McDermorr WV, Jr., Morgan WS, Hamlin E, Jr., et al.: Cancer of the thyroid. J Clin Endocrinol Metab 1954;14:1336-1354.
4. Byar DP, Green SB, Dor P, et al.: A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group. Eur J Cancer 1979;15:1033-1041.
5. Kukkonen ST, Haapiainen RK, Granssila KO, et al.: Papillary thyroid carcinoma: The new, age-related TNM classification system in a retrospective analysis of 199 patients. World J Surg 1990;14:837-842.
6. Hay ID, Taylor WF, McConahey WM: A prognostic score for predicting outcome in papillary thyroid carcinoma. Endocrinology 1986;119:T-15.
7. Cady B: Our AMES is true: How an old concept still hits the mark: Or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997:462-468.
8. Hay ID, Bergstralh EJ, Goellner JR, et al.: Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-1058.
9. Shaha AR, Shah JP, Loree TR: Low-risk differentiated thyroid cancer: The need for selective treatment. Ann Surg Oncol 1997;4:328-333.
10. Hay ID, McConahey WM, Goellner JR: Managing patients with papillary thyroid carcinoma: Insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Amer Clin Climatol Assoc 2002;113:241-260.
11. Cady B: Staging in thyroid carcinoma. Cancer 1998;83:844-847.
12. Cooper DS, Doherty GM, Haugen BR, et al.: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:4-33.
13. Powell JG, Hay ID: Papillary Carcinoma of the Thyroid. In: Randolph GD. editor. Surgery of the Thyroid and Parathyroid Glands. Philadelphia, Pennsylvania: Saunders, 2003. 188-211.
14. 131I in the treatment of well differentiated thyroid cancer. J Surg Oncol 2005;89:114-121.
15. Machens A, Holzhausen HJ, Dralle H: The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005;103:2269-2273.
16. Podnos YD, Smith D, Wagman LD, et al.: Radioactive iodine offers survival improvement in patients with follicular carcinoma of the thyroid. Surgery 2005;138:1072-1077.
17. Kouvaraki MA, Lee JE, Shapiro SE, et al.: Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 2004;136:1183-1191.
18. Brierley J, Tsang R, Panzarella T, et al.: Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clinical Endocrinology 2005;63:418-427.
19. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005;353:487-497.
20. Kebebew E, Peng M, Reiff E, et al.: Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer 2006;106:2592-2597.
21. Lubitz CC, Gallagher LA, Finley DJ, et al.: Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery 2005;138:1042-1048.
22. Kebebew E, Peng M, Reiff E, et al.: Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Surgery 2005;138:1102-1110.
23. Carlomagno F, Anaganti S, Guida T, et al.: BAY 43-9006 inhibition of oncogenic RET mutants. J Nat Cancer Inst 2006;98:326-334.
24. Nakazawa T, Kondo T, Kobayashi Y, et al.: RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan). Cancer 2005;104:943-951.
25. Hundahl SA, Cady B, Cunningham MP, et al.: For the U.S. and German Thyroid Cancer Study Group. Communication from the American College of Surgeons Commission on Cancer and the American Cancer Society. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996: An American College of Surgeons Commission on Cancer Patient Care Evaluation Study. Cancer 2000;89:202-217.
26. Holzer S, Reiners C, Mann K, et al.: Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. Cancer 2000;89:192-201.
27. Hodgson NC, Button J, Solorzano CC: Thyroid cancer; Is the incidence still increasing? Ann Surg Oncol 2004;11:1093-1097.